Ivacaftor
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator — RESPIRATORY SYSTEM
Also known as: kalydeco, VX 770
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ivacaftor is an onp drug in the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Chloride Channel Activation Potentiators, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inhibitors. DrugCentral lists 1 molecular target, including CFTR. Recorded indications include Cystic fibrosis of the lung.
- Approval status: onp (first approved 2012 by the FDA).
- Drug class: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator.
- Mechanism of action: Chloride Channel Activation Potentiators; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inhibitors.
- Molecular targets: CFTR (1 listed in DrugCentral).
- Indications: Cystic fibrosis of the lung.
- ATC code: R07AX02 (Other respiratory system products).
- Molecular formula: C24H28N2O3; molecular weight 392.50 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Cystic fibrosis of the lung
Mechanism & targets
| Mechanism of action (MoA) | Chloride Channel Activation Potentiators; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inhibitors; P-Glycoprotein Inhibitors |
|---|---|
| Established pharmacologic class | Cystic Fibrosis Transmembrane Conductance Regulator Potentiator |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Cystic fibrosis transmembrane conductance regulator | CFTR | other | EC50 8.52 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2020-08-21 | EMA | — | Vertex Pharmaceuticals (Ireland) Limited | Yes |
| 2012-01-31 | FDA | — | VERTEX PHARMS | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R07AX02 | RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products |
R07AX30 | RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products |
R07AX31 | RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products |
R07AX32 | RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: CFTR · Testing Required
- FDA label: CFTR · Testing Required
- HCSC label: CFTR · Testing Required
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Infective pulmonary exacerbation of cystic fibrosis | 1869.1 |
| Hospitalisation | 309.1 |
| Pulmonary function test decreased | 149.2 |
| Cystic fibrosis respiratory infection suppression | 124.7 |
| Haemoptysis | 99.6 |
| Amniotic fluid index increased | 95.0 |
| Forced expiratory volume decreased | 94.8 |
| Distal intestinal obstruction syndrome | 83.5 |
| Left-to-right cardiac shunt | 80.1 |
| Foetal macrosomia | 80.0 |
| Alanine aminotransferase increased | 73.2 |
| Abortion spontaneous | 69.9 |
Chemical structure
| Molecular formula | C24H28N2O3 |
|---|---|
| Molecular weight | 392.50 g/mol |
| CAS number | 873054-44-5 |
| InChIKey | PURKAOJPTOLRMP-UHFFFAOYSA-N |
| PubChem CID | 16220172 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ivacaftor used for?
DrugCentral lists the following indications for Ivacaftor: Cystic fibrosis of the lung.
How does Ivacaftor work?
Ivacaftor is classified as Chloride Channel Activation Potentiators, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inhibitors; its molecular targets in DrugCentral include CFTR.
When was Ivacaftor first approved?
Ivacaftor was first approved by the FDA in 2012.
What drug class does Ivacaftor belong to?
Ivacaftor is in the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator class.
What is the chemical formula of Ivacaftor?
Ivacaftor has the molecular formula C24H28N2O3 and a molecular weight of 392.50 g/mol.
Browse: all drugs starting with I · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4228 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2010601 — compound record and bioactivity
- PubChem CID 16220172 — chemical identifiers
- DrugBank DB08820 — drug record
- FDA UNII 1Y740ILL1Z — substance identity
- DailyMed: FDA labels for Ivacaftor — current prescribing information (label search)
- UniProt P13569 (CFTR) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.